NCT05328024View on ClinicalTrials.gov

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

August 25, 2029

Study Completion Date

August 25, 2029

Conditions
Head and Neck Cancer
Interventions
DRUG

Immunotherapy

anti-PD1

Trial Locations (1)

67033

RECRUITING

Institut de cancérologie Strasbourg Europe, Strasbourg

All Listed Sponsors
collaborator

Centre National de la Recherche Scientifique, France

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Institut de cancérologie Strasbourg Europe

OTHER